This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the
investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with
myeloid cells collected from the patient's blood. The myeloid cells are modified and
later infused back into their veins. The modified myeloid cells recognize the tumor cells
and are designed to target and kill them.
Additional locations may be listed on ClinicalTrials.gov for NCT05138458.
See trial information on ClinicalTrials.gov for a list of participating sites.
The research study is divided into two parts. The first part will be to determine the
safety and tolerability of the study drug product. During this part of the study, there
will be 4 groups of study patients. The first group of patients will receive a low dose
of cells, the second group will receive the low dose of cells and lymphodepleting
chemotherapy to reduce the number of T cells in the blood, the third group will receive a
higher dose of cells, and the fourth group will receive the higher dose of cells and
lymphodepleting chemotherapy to reduce the number of T cells in the blood. In the second
part of the study, cells with or without chemotherapy will be administered based on
results of Part 1 and the safety, tolerability, and efficacy of MT-101 will be assessed.
All patient groups will receive 6 doses of drug product over 3 weeks.
Lead OrganizationMyeloid Therapeutics
